海南医科大学学报

目的:探讨噻托溴铵粉雾剂治疗慢性阻塞性肺疾病(COPD)的临床效果。方法:70例COPD患者随机分为观察组与对照组,每组35例,观察组给予噻托溴铵粉雾剂治疗,对照组给予口服氨茶碱治疗,对比两组临床表现、肺功能及转化生长因子β1(TGF-β1)情况。结果:观察组治疗后临床总改善率(80.0%)显著高于对照组(51.4%)(P<0.05);观察组治疗后FEV1、FVC均显著高于治疗前(P<0.05),且显著高于对照组(P<0.05),而对照组则未见显著变化(P>0.05);两组治疗前TGF-β1阳性率无显著差异(P>0.05),观察组治疗后(28.6%)显著低于治疗前(62.9%)(P<0.01),且显著低于对照组(54.3%)(P<0.05),对照组治疗前后无显著差异(P>0.05)。结论:噻托溴铵粉雾剂用于COPD的治疗,可有效缓解临床症状体征,改善肺功能,有效延缓气道重塑,且并未增加不良反应的发生率,安全可靠,值得推广。

Objective: To explore the clinical efficacy of tiotropium bromide powder on chronic obstructive pulmonary diseases(COPD).Methods:A total of 70 patients with COPD were randomly divided into the observation group(n=35) and that of the control group(n=35).Tiotropium bromide powder was given to patients in the observation group,while aminophylline was given to the control group,then the clinical symptoms and signs,lung function,TGF-β1 of sputum,and the adverse reactions were observed and compared between the two groups.Results:Total clinical improvement rate in the observation group(80.0%) was significantly higher than that of the control group(51.4%)(P<0.05);FEV1,FVC was significantly higher after treatment in the observation group(P<0.05),and they were significantly higher than that of the control group(P<0.05);positive rate of sputum TGF-β1(28.6%) in the observation group was significantly lower after treatment(62.9%)(P<0.01),and it was also significantly lower than that of the control group(54.3%)(P<0.05);there was no significantly difference in the adverse reaction between two groups(P>0.05).Conclusions:Tiotropium bromide powder can effectively alleviate clinical signs and symptoms,improve lung function,effectively delay the airway remodeling,without increasing the incidence of adverse reactions.It is safe and reliable,and is worth promoting.